image
Healthcare - Biotechnology - NASDAQ - US
$ 1.365
8.66 %
$ 49 M
Market Cap
-0.68
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one IMRX stock under the worst case scenario is HIDDEN Compared to the current market price of 1.36 USD, Immuneering Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one IMRX stock under the base case scenario is HIDDEN Compared to the current market price of 1.36 USD, Immuneering Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one IMRX stock under the best case scenario is HIDDEN Compared to the current market price of 1.36 USD, Immuneering Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IMRX

image
$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
-64.1 B OPERATING INCOME
-109587.10%
-61 M NET INCOME
-14.15%
-55 M OPERATING CASH FLOW
-12.32%
26.4 M INVESTING CASH FLOW
262.30%
5.3 M FINANCING CASH FLOW
-81.35%
0 REVENUE
0.00%
-18.6 M OPERATING INCOME
-21.50%
-18.1 M NET INCOME
-23.66%
-14.5 M OPERATING CASH FLOW
-7.71%
5.49 M INVESTING CASH FLOW
201.39%
-41 K FINANCING CASH FLOW
-0.94%
Balance Sheet Immuneering Corporation
image
Current Assets 39.6 B
Cash & Short-Term Investments 36.1 B
Receivables 0
Other Current Assets 3.44 B
Non-Current Assets 13.1 B
Long-Term Investments 0
PP&E 4.79 B
Other Non-Current Assets 8.34 B
68.57 %6.53 %9.09 %15.81 %Total Assets$52.7b
Current Liabilities 7.5 B
Accounts Payable 1.96 M
Short-Term Debt 338 K
Other Current Liabilities 7.5 B
Non-Current Liabilities 3.82 B
Long-Term Debt 3.83 B
Other Non-Current Liabilities -3.82 M
66.22 %33.79 %Total Liabilities$11.3b
EFFICIENCY
Earnings Waterfall Immuneering Corporation
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 64.1 B
Operating Income -64.1 B
Other Expenses -64 B
Net Income -61 M
00(10b)(10b)(20b)(20b)(30b)(30b)(40b)(40b)(50b)(50b)(60b)(60b)(70b)(70b)000(64b)(64b)64b(61m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-147.48% ROE
-147.48%
-115.79% ROA
-115.79%
-141.72% ROIC
-141.72%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Immuneering Corporation
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)202020202021202120222022202320232024202420252025
Net Income -61 M
Depreciation & Amortization 0
Capital Expenditures -84.9 K
Stock-Based Compensation 6.5 M
Change in Working Capital -925 K
Others -352 K
Free Cash Flow -55.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Immuneering Corporation
image
Wall Street analysts predict an average 1-year price target for IMRX of $17.5 , with forecasts ranging from a low of $3 to a high of $41 .
IMRX Lowest Price Target Wall Street Target
3 USD 119.78%
IMRX Average Price Target Wall Street Target
17.5 USD 1182.05%
IMRX Highest Price Target Wall Street Target
41 USD 2903.66%
Price
Max Price Target
Min Price Target
Average Price Target
454540403535303025252020151510105500Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership Immuneering Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place from April 7-10, 2025, to discuss the company's pipeline, platform, and business strategy. globenewswire.com - 1 month ago
Immuneering Corporation Announces Grant of Inducement Award CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, previously announced on March 20, 2025, that Igor Matushansky, M.D. globenewswire.com - 1 month ago
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in non-small cell lung cancer - - Additional IMM-1-104 Phase 2a data updates and initiation of new IMM-1-104 combination arms expected in 2025; planning underway for potential IMM-1-104 global pivotal trial - - Named industry veteran Dr. Igor Matushansky as Chief Medical Officer - - Cash runway extended into 2026 - CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business updates. globenewswire.com - 1 month ago
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that Igor Matushansky, MD, PhD, has joined the company as Chief Medical Officer. globenewswire.com - 1 month ago
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 11-12, 2025, to discuss the company's pipeline, platform, and business strategy. globenewswire.com - 2 months ago
Why Is Immuneering Stock Trading Higher On Tuesday? On Tuesday, Immuneering Corporation IMRX revealed data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104 and plans to expand the Phase 2a trial to include three additional combination arms. benzinga.com - 3 months ago
Immuneering Launches Pancreatic Cancer Advisory Board - Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 - CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the formation of its Pancreatic Cancer Advisory Board. globenewswire.com - 4 months ago
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. benzinga.com - 4 months ago
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma - IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors - - IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma - - Melanoma patients actively enrolling in one of five arms in the company's ongoing Phase 2a clinical study of IMM-1-104 - CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead clinical-stage program, IMM-1-104, as a treatment for patients with unresectable or metastatic NRAS-mutant melanoma who have progressed on or are intolerant to PD-1/PD-L1 based immune checkpoint inhibitors. globenewswire.com - 4 months ago
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference, which is taking place at the Lotte New York Palace in New York City from December 3-5, 2024, to discuss the company's pipeline, platform, and business strategy. globenewswire.com - 5 months ago
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - - Granted FDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer and Fast Track Designation in First-line Pancreatic Cancer - - Initial Data From At Least One Additional Arm of the Phase 2a Portion of the IMM-1-104 Phase 1/2a Trial Expected by Year End - - Cash Runway into Fourth Quarter 2025 - CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided business updates. globenewswire.com - 5 months ago
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug The FDA bestows an orphan drug designation to Immuneering's lead candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares rise. zacks.com - 6 months ago
8. Profile Summary

Immuneering Corporation IMRX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 49 M
Dividend Yield 0.00%
Description Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Contact 245 Main Street, Cambridge, MA, 02142 https://immuneering.com
IPO Date July 30, 2021
Employees 66
Officers Dr. Benjamin J. Zeskind M.B.A., Ph.D. Co-Founder, President, Chief Executive Officer & Director Dr. Brett M. Hall Ph.D. Chief Scientific Officer Ms. Paula George CPA Director of Accounting & Operations and Assistant Corporate Controller Mr. Harold E. Brakewood Chief Business Officer Ms. Mallory Morales CPA Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer Dr. Praveen Nair Ph.D. Head of Translational Pharmacology & Vice President Mr. Michael D. Bookman J.D. Chief Legal Officer & Secretary Ms. Leah R. Neufeld Chief People Officer Dr. Peter King Ph.D. Head of Discovery & Vice President Mr. Robert J. Carpenter M.B.A., M.S. Co-Founder & Chair Emeritus